GlassScriptPhysician profile
Mercy Stanley
NPI 1548511603
$3,681.47
in general payments reported to CMS, 2019-2025
24 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.63 · 2022: $163 · 2023: $935 · 2024: $1,222 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933 · Education: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,932.76 |
| Education | $518.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,084.78 | 2022-2025 | Xospata, Cresemba |
| Incyte Corporation | $322.75 | 2022-2025 | Jakafi, Niktimvo |
| Lilly USA, LLC | $311.44 | 2023-2025 | Jaypirca |
| Astrazeneca Pharmaceuticals LP | $260.29 | 2021-2025 | Calquence |
| Sobi, INC | $196.21 | 2024-2025 | |
| Daiichi Sankyo INC. | $195.50 | 2023-2024 | Vanflyta, Enhertu |
| Syndax Pharmaceuticals, INC. | $195.36 | 2025 | |
| Celgene Corporation | $134.41 | 2023-2025 | Reblozyl |
| Beigene USA, INC. | $132.38 | 2024 | Brukinsa |
| Abbvie INC. | $131.40 | 2021-2025 | |
| Pharmaessentia USA Corporation | $115.79 | 2023-2024 | Besremi |
| Novartis Pharmaceuticals Corporation | $106.60 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $74.25 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $62.55 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pfizer INC. | $58.11 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.16 | 2023 | Blincyto, Kyprolis |
| Janssen Biotech, INC. | $53.26 | 2023 | Imbruvica |
| Taiho Oncology, INC. | $33.66 | 2024 | |
| Blueprint Medicines Corporation | $32.22 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $30.06 | 2024 | Ojjaara |
| Merck Sharp & Dohme LLC | $27.91 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $26.52 | 2024 | Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $24.28 | 2023 | Epkinly, Imbruvica |
| Adaptive Biotechnologies Corporation | $17.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mercy Stanley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.